Literature DB >> 29203362

HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors.

Hideyuki Ujiie1, Ken Muramatsu2, Taisei Mushiroda3, Takeshi Ozeki3, Hideaki Miyoshi4, Hiroaki Iwata2, Akinobu Nakamura4, Hiroshi Nomoto4, Kyu Yong Cho4, Norihiro Sato5, Machiko Nishimura2, Takamasa Ito2, Kentaro Izumi2, Wataru Nishie2, Hiroshi Shimizu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29203362     DOI： 10.1016/j.jid.2017.11.023

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  26 in total

1.  Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions.

Authors:  Yoshifumi Saisho
Journal:  Ann Transl Med       Date:  2018-04

2.  Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.

Authors:  Arata Hibi; Yuto Kasahara; Yoshitaka Ishihara; Koichi Hata; Norihisa Hosokawa; Takahiko Nakagawa
Journal:  CEN Case Rep       Date:  2020-01-28

Review 3.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

5.  Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans.

Authors:  Enno Schmidt; Saleh M Ibrahim; Christian Schwarm; Damian Gola; Maike M Holtsche; Anabelle Dieterich; Anita Bhandari; Miriam Freitag; Peter Nürnberg; Mohammad Toliat; Wolfgang Lieb; Michael Wittig; André Franke; Margitta Worm; Michael Sticherling; Jan Ehrchen; Claudia Günther; Regine Gläser; Wiebke K Peitsch; Miklós Sárdy; Rüdiger Eming; Michael Hertl; Sandrine Benoit; Matthias Goebeler; Claudia Pföhler; Manfred Kunz; Alexander Kreuter; Nina van Beek; Jeanette Erdmann; Hauke Busch; Detlef Zillikens; Christian D Sadik; Misa Hirose; Inke R König
Journal:  Orphanet J Rare Dis       Date:  2021-05-19       Impact factor: 4.123

6.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

7.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

Review 8.  Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.

Authors:  Yosuke Mai; Wataru Nishie; Kazumasa Sato; Moeko Hotta; Kentaro Izumi; Kei Ito; Kazuyoshi Hosokawa; Hiroshi Shimizu
Journal:  Front Immunol       Date:  2018-04-12       Impact factor: 7.561

Review 9.  The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations.

Authors:  Khalaf Kridin; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2018-08-20

Review 10.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.